) declared that the Journal of Clinical Oncology (JCO) has
published positive results for a study of the company's Oncotype
DX colon cancer test. The study was conducted on patients from
the National Surgical Adjuvant Breast and Bowel Project (NSABP)
C-07 clinical trial.
The study also holds that recurrence risk can be determined
through Oncotype DX Recurrence Score (RS) results. RS can also
provide information apart from conventional risk factors, helping
better discrimination of absolute benefit of chemotherapy as a
function of risk.
As per this large, independent validation study, patients with
a high RS result should derive larger absolute chemotherapy
treatment benefit than patients with a low RS one, in both stage
II and stage III colon cancer. Besides determining risk of
recurrence, the RS results provide disease-free survival and
overall survival in stage II and stage III colon cancer patients
receiving adjuvant chemotherapy (all p<0.001).
This study marks the third successful prospectively designed
study of the Oncotype DX colon cancer test in patients with stage
II disease and the first validation study in patients with stage
The Oncotype DX colon cancer test is yet to make any
significant contribution to the top line (less than 5% of total
test volume). The path to manage reimbursement for the test has,
to date, been a little difficult.
Yet, we are encouraged by Medicare's decision in the
sequentially last quarter to cover stage II colon cancer patients
with a new policy. Moreover, market opportunity continues to
grow, with colon cancer being the fifth-most common cancer and
the third-most common cause of cancer mortality in the world.
In the coming months, Genomic Health plans to conduct a colon
oxaliplatin treatment validation study for prediction and will
begin a large clinical study using next-generation sequencing and
fixed paraffin-embedded tissue.
The stock presently carries a Zacks Rank #3 (Hold). On the
other hand, medical sector stocks that warrant a look are
Align Technologies Inc.,
Cardinal Health, Inc.
Mindray Medical International Limited
). All these stocks carry a Zacks Rank #1 (Strong
ALIGN TECH INC (ALGN): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.